-
Posted by
Two Blokes May 23 -
Filed in
Stock
-
4 views
VANCOUVER, BC / ACCESS Newswire / May 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that the examining division of the European Patent Office ("EPO") has provided formal notice of the EPO‘s intention to grant BioNxt its core patent without significant changes. The Company's core patent filing was a comprehensive application for the sublingual delivery of anticancer drugs for the treatment of autoimmune neurodegenerative diseases.
